Sirolimus and novel mTOR inhibitors are currently being tested in clinical trials in PD and multiple system atrophy (MSA) patients (clinicaltrials.gov: NCT03589976; anzctr.org.au: ACTRN12619000372189). Here, MTOR is linked to multiple system atrophy.